Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
A holder of Common stock has filed a notice of proposed sale of 2,000 shares, with an aggregate market value of $6,180.00, through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 01/27/2026 on the NASDAQ. The issuer has 37,627,034 shares of this class outstanding. The shares to be sold were acquired as Restricted Stock Units from the issuer on 02/06/2024, in an amount of 2,000 shares.
Over the prior three months, the same account reported several sales of the issuer’s common stock, including 2,000 shares for $6,002.60 on 12/30/2025, 616 shares for $2,038.96 on 12/10/2025, 2,000 shares for $5,862.80 on 12/02/2025, 6,528 shares for $17,103.36 on 11/10/2025, and 2,000 shares for $6,141.00 on 11/04/2025, some of which are identified as 10b5-1 sales.
Sera Prognostics, Inc. received an updated large shareholder report showing that Whetstone Capital Advisors, LLC and David Atterbury together beneficially own 3,459,713 shares of its Class A common stock, representing 9.2% of the class. The filing states that the reporting persons share voting and dispositive power over these shares. They also certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Sera Prognostics, but instead are reported on a passive basis under Schedule 13G/A.
Sera Prognostics, Inc. filed a current report to note that it has posted a new investor presentation on its corporate website as of January 8, 2026. The presentation is included as Exhibit 99.1 to the report and is incorporated by reference for informational purposes. The company specifies that this material is being furnished under Regulation FD and is not deemed filed for liability purposes under the Exchange Act or automatically incorporated into other securities filings.
Sera Prognostics, Inc. filed a current report to highlight a communication event rather than a financial update. On January 7, 2026, the company issued a press release announcing publication of the results of its Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study in the Pregnancy Journal.
The newly published PRIME study results are scheduled to be discussed during a Jefferies-hosted fireside chat on January 9, 2026, at 8:30 am ET. The press release is furnished as Exhibit 99.1 and, along with the related disclosure under Item 7.01, is treated as "furnished" rather than "filed" for liability purposes under the Exchange Act.
Sera Prognostics, Inc. reported that its Chief Data Officer sold 1,213 shares of Class A common stock on 12/10/2025 at a weighted average price of $3.31 per share. These shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units, under the company's mandated "sell to cover" election, so the transaction was not discretionary. Following this sale, the officer beneficially owned 167,383 shares of Class A common stock directly.
Sera Prognostics, Inc. reported that its Chief Information Officer, an officer of the company, sold 616 shares of Class A common stock on 12/10/2025 at a weighted average price of $3.31.
According to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units under a sale structure mandated by the company’s sell-to-cover election, and the transaction is not discretionary for the officer. Following this sale, the officer beneficially owns 86,788 shares directly.
Sera Prognostics, Inc. disclosed that its Chief Executive Officer and director reported a sale of Class A common stock under a Form 4 filing. On 12/09/2025, the reporting person sold 28,215 shares of Class A common stock in a transaction coded "S" at a weighted average price of $3.04 per share. After this transaction, the executive beneficially owned 768,081 shares directly.
The company explains that the shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units. The sale was carried out under the issuer’s election to satisfy tax obligations through mandated “sell to cover” transactions, meaning it was not a discretionary trade by the executive. The price reflects a block trade executed in multiple transactions at prices between $2.91 and $3.10 per share.
Sera Prognostics, Inc. director reported an open-market sale of company stock. On 12/08/2025, the reporting person sold 1,560 shares of Class A Common Stock at a weighted average price of $3.05 per share, with individual trade prices ranging from $2.99 to $3.11. The sale was made under a Rule 10b5-1 trading plan that the insider adopted on June 10, 2025. After this transaction, the insider beneficially owns 19,593 shares of Sera Prognostics common stock in direct form.
Sera Prognostics, Inc. filed a current report to share that findings from its Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (“PRIME”) study have been accepted for publication in a peer-reviewed journal. The company disclosed this information under a Regulation FD disclosure, indicating it was also announced in a press release dated November 24, 2025, furnished as an exhibit to the report.
Sera Prognostics (SERA) filed its Q3 2025 report, highlighting modest revenue and a continued focus on funding and operations. Revenue was $16 thousand for the quarter and $71 thousand year-to-date. The company reported a Q3 net loss of $7.8 million and a year-to-date net loss of $24.0 million, driven by operating expenses of $9.0 million in the quarter.
Liquidity strengthened earlier in the year from a February 2025 underwritten offering, delivering $53.6 million in net proceeds. As of September 30, 2025, cash, cash equivalents and marketable securities totaled $102.4 million, with total assets of $108.1 million and stockholders’ equity of $82.2 million. Operating cash used year-to-date was $19.5 million. Deferred revenue stood at $20.3 million, reflecting contractual arrangements to be recognized upon delivery of test results. The company amended and extended its headquarters lease in September 2025, with a noncurrent operating lease obligation of $2.4 million.